Anders Ekblom Net Worth

Anders Ekblom biography

Dr. Anders Ekblom serves as Non-Executive Independent Director of the Company. Mr. Blackburn has served on our Board since October 2015. Mr. Blackburn was Senior Vice President Strategic Finance Projects and Financial Controller at GlaxoSmithKline. Mr. Blackburn currently serves on the Board of Directors of Syngene. Mr. Blackburn is a member of the Chartered Institute of Management Accountants. Mr. Blackburn holds a B.Sc. from Warwick University.

What is the salary of Anders Ekblom?

As the Non-Executive Independent Director of Mereo BioPharma plc, the total compensation of Anders Ekblom at Mereo BioPharma plc is $48,000. There are 9 executives at Mereo BioPharma plc getting paid more, with Denise Scots-Knight having the highest compensation of $1,176,190.

How old is Anders Ekblom?

Anders Ekblom is 65, he's been the Non-Executive Independent Director of Mereo BioPharma plc since 2015. There are 3 older and 18 younger executives at Mereo BioPharma plc. The oldest executive at Mereo BioPharma Group plc is Peter Fellner, 76, who is the Non-Executive Independent Chairman of the Board.

What's Anders Ekblom's mailing address?

Anders's mailing address filed with the SEC is C/O MEREO BIOPHARMA GROUP PLC, 4TH FLOOR, ONE CAVENDISH PLACE, LONDON, X0, W1G 0QF.

Insiders trading at Mereo BioPharma plc

Over the last few years, insiders at Mereo BioPharma plc have traded over $974,160 worth of Mereo BioPharma plc stock. The most active insiders traders include Capital Management Lp Rosen..., Deepika Pakianathan a Denise Scots Knight. On average, Mereo BioPharma plc executives and independent directors trade stock every 8 days with the average trade being worth of $447,435. The most recent stock trade was executed by Deepika Pakianathan on 22 August 2024, trading 105,244 units of MREO stock currently worth $151,551.

What does Mereo BioPharma plc do?

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom.

Mereo BioPharma plc executives and stock owners

Mereo BioPharma plc executives and other stock owners filed with the SEC include:

• Denise Scots-Knight,
  Chief Executive Officer, Co-Founder, Executive Director
• Dr. Denise Scots-Knight Ph.D.,
  Co-Founder, CEO & Exec. Director
• Charles Sermon,
  Co-Founder, Gen. Counsel & Company Sec.
• Dr. Alastair MacKinnon M.D., MBBS,
  Co-Founder and Chief of Portfolio & Pipeline Strategy
• Dr. John P. Richard M.B.A., MBA,
  Co-Founder & Chief Bus. Officer
• Dr. John A. Lewicki Ph.D.,
  Chief Scientific Officer
• Alexandra Hughes-Wilson,
  Chief of Patient Access & Commercial Planning
• Richard Jones,
  Chief Financial Officer, Executive Director
• Peter Fellner,
  Non-Executive Independent Chairman of the Board
• Anders Ekblom,
  Non-Executive Independent Director
• Peter Bains,
  Non-Executive Independent Director
• Kunal Kashyap,
  Non-Executive Independent Director
• Michael Wyzga,
  Non-Executive Independent Director
• Deepa Pakianathan,
  Non-Executive Independent Director
• Brian Schwartz,
  Director
• Jeremy Bender,
  Director
• Wills Hughes-Wilson,
  Head of Patient Access, Commercial Planning
• Heidi Petersen,
  Senior Vice President, Regulatory Affairs
• Jill Henrich,
  U.S. Site Head and Senior Vice President of Regulatory Affairs
• John Richard,
  Head of Corporate Development, Co-Founder
• Alastair MacKinnon,
  Co-Founder, Chief Medical Officer
• Charles Sermon,
  Co-Founder, General Counsel, Company Secretary
• Dr. Arun Mistry,
  Therapeutic Area Head of Setrusumab
• Dr. Jackie Parkin,
  Therapy Area Head of Respiratory Endocrinology
• Ian Hodgson,
  Head of Clinical Operations
• Dr. Fiona Bor,
  Head of Intellectual Property
• Dr. John A. Lewicki,
  Chief Scientific Officer
• Christine Fox CPA,
  Chief Financial Officer
• Jill Henrich,
  US Site Head & Sr. VP of Regulatory Affairs
• John Richard,
  Co-Founder & Head of Corp. Devel.
• Dr. Alastair MacKinnon,
  Co-Founder & Chief Medical Officer
• Dr. Denise Scots-Knight,
  Co-Founder, CEO & Exec. Director
• Capital Management Lp Rosen...,
  
• Marc J Yoskowitz,
  
• Annalisa Jenkins,
  
• Daniel Shames,
  
• Deepika Pakianathan,
  
• Pierre Jacquet,
  
• Christine Ann Fox,
  Chief Financial Officer
• John A. Lewicki,
  Chief Scientific Officer